文献速递产科

门诊宫颈成熟:系统综述与荟萃分析

Outpatient Cervical Ripening: A Systematic Review and Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2021-01-01

该系统综述与荟萃分析纳入30项随机对照试验和10项队列研究(N=9,618),比较门诊与住院宫颈成熟或门诊不同成熟方法的效果与危害。主要针对低危妊娠孕妇,发现门诊使用地诺前列酮或单球囊导管不增加剖宫产率,但证据质量低或不足,危害报告不一致,无法得出确定性结论。

要点

  • 门诊宫颈成熟使用地诺前列酮或单球囊导管不增加剖宫产。
  • 门诊与住院比较,新生儿感染、产伤、肩难产等危害无显著差异。
  • 证据质量低或不足,危害报告不一致,需谨慎解读。

核心结论

  • 低危妊娠孕妇门诊宫颈成熟使用地诺前列酮或单球囊导管不增加剖宫产。
  • 门诊与住院宫颈成熟的危害无明确差异,但证据确定性低或不足。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE等数据库至2020年8月。
  • 纳入30项随机对照试验和10项队列研究,共9,618例孕37周及以上孕妇。
  • 研究对象多可推广至25-30岁低危妊娠孕妇。

主要发现

  • 所有比较的剖宫产发生率无统计学显著差异。
  • 门诊与住院地诺前列酮比较,新生儿感染(如败血症)无差异。
  • 门诊与住院单球囊导管比较,产伤(如头颅血肿)和母体感染(如绒毛膜羊膜炎)无差异。
  • 门诊地诺前列酮与安慰剂比较,肩难产无差异。
  • 门诊前列腺素与安慰剂比较,母体感染无差异;门诊导管与住院地诺前列酮比较,产后出血无差异。

关键数值与推荐

  • 所有发现证据强度低或不足,且无统计学显著性。
  • 米索前列醇、吸湿性扩张器及其他结局(如围产儿死亡、至阴道分娩时间)证据不足。

临床怎么用

  • 低危妊娠孕妇可考虑门诊使用地诺前列酮或单球囊导管进行宫颈成熟。
  • 需告知患者证据质量低,危害报告不一致,决策应个体化。

局限性

  • 危害报告不一致或定义不充分。
  • 证据质量低或不足,无法得出确定性结论。
  • 研究人群多限于低危妊娠,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the comparative effectiveness and potential harms of cervical ripening in the outpatient compared with the inpatient setting, or different methods of ripening in the outpatient setting alone. DATA SOURCES: Searches for articles in English included MEDLINE, EMBASE, CINAHL, Cochrane Library, ClinicalTrials.gov, and reference lists (up to August 2020). METHODS OF STUDY SELECTION: Using predefined criteria and DistillerSR software, 10,853 citations were dual-reviewed for randomized controlled trials (RCTs) and cohort studies of outpatient cervical ripening using prostaglandins and mechanical methods in pregnant women at or beyond 37 weeks of gestation. TABULATION, INTEGRATION, AND RESULTS: Using prespecified criteria, study data abstraction and risk of bias assessment were conducted by two reviewers, random-effects meta-analyses were conducted and strength of evidence was assessed. We included 30 RCTs and 10 cohort studies (N=9,618) most generalizable to women aged 25-30 years with low-risk pregnancies. All findings were low or insufficient strength of evidence and not statistically significant. Incidence of cesarean delivery was not different for any comparison of inpatient and outpatient settings, or comparisons of different methods in the outpatient setting (most evidence available for single-balloon catheters and dinoprostone). Harms were inconsistently reported or inadequately defined. Differences were not found for neonatal infection (eg, sepsis) with outpatient compared with inpatient dinoprostone, birth trauma (eg, cephalohematoma) with outpatient compared with inpatient single-balloon catheter, shoulder dystocia with outpatient dinoprostone compared with placebo, maternal infection (eg, chorioamnionitis) with outpatient compared with inpatient single-balloon catheters or outpatient prostaglandins compared with placebo, and postpartum hemorrhage with outpatient catheter compared with inpatient dinoprostone. Evidence on misoprostol, hygroscopic dilators, and other outcomes (eg, perinatal mortality and time to vaginal birth) was insufficient. CONCLUSION: In women with low-risk pregnancies, outpatient cervical ripening with dinoprostone or single-balloon catheters did not increase cesarean deliveries. Although there were no clear differences in harms when comparing outpatient with inpatient cervical ripening, the certainty of evidence is low or insufficient to draw definitive conclusions. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42020167406.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. McDonagh M, Skelly AC, Tilden E, et al. Outpatient Cervical Ripening: A Systematic Review and Meta-analysis. Obstet Gynecol. 2021. PMID: 33752219. doi:10.1097/AOG.0000000000004382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。